ERYTECH reports additional positive Phase III results from clinical study with eryaspase/GRASPA® in Acute Lymphoblastic Leukemia Post author:admERY Post published:December 8, 2014 Post category:Newsroom ERYTECH reports additional positive Phase III results from the pivotal study with eryaspase/GRASPA® in Acute Lymphoblastic Leukemia. You Might Also Like PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences September 5, 2023 ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2019 November 7, 2019 ERYTECH makes its 2015 Reference Document available April 30, 2016
PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences September 5, 2023
ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2019 November 7, 2019